Skip directly to content

Community Survey on PrEP and Biomedical Prevention Clinical Trials

Treatment Action Group (TAG) is interested in learning more about your perspectives on the provision of Truvada for pre-exposure prophylaxis (PrEP) in clinical trials of biomedical prevention interventions (e.g. HIV vaccines, antibody or immune-based prevention interventions, and other forms of antiviral PrEP).

Guidelines[1] recommend that the state of the art package of prevention services (risk reduction counseling, condoms and lube, circumcision, and/or PrEP) known as the "standard of prevention" be provided to all HIV prevention clinical trial participants. The effect of an experimental intervention is tested to see if it can further reduce the risk of HIV acquisition when given in addition to this standard of prevention.

Truvada PrEP is efficacious when used consistently and is recommended for individuals at high risk of HIV acquisition. However, there remains some uncertainty regarding how Truvada PrEP should be incorporated into the package of prevention options offered to clinical trial participants.

The purpose of this brief survey is to help inform research sponsors, study investigators, and activists about the opinions of community leaders and activists regarding the provision of Truvada PrEP in clinical trials of biomedical prevention interventions.

The questionnaire will require approximately 15 minutes of your time and will close Monday, March 20th, at 5:00pm ET. Please feel free to distribute this survey to appropriate colleagues. The survey can be completed anonymously and is not seeking information on specific community advisory bodies.

We thank you for your contribution to this effort.



[1] UNAIDS. Ethical considerations in biomedical HIV prevention trials. Geneva: UNAIDS; 2007 [updated 2012].